Human Papillomavirus (HPV) Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety Profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
Condition: Human Papillomavirus Infection Interventions: Biological: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli); Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)(GARDASIL®) Sponsor: Beijing Health Guard Biotechnology, Inc Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 30, 2022 Category: Research Source Type: clinical trials
A Phase III Trial Evaluates the Efficacy, Immunogenicity and Safety Profile of HPV Vaccine
Condition: Human Papillomavirus Infection Interventions: Biological: Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli); Biological: Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)(GARDASIL®) Sponsor: Beijing Health Guard Biotechnology, Inc Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 30, 2022 Category: Research Source Type: clinical trials